SCHEMBL14073451

SCHEMBL14073451

Nc1ncccc1C(=O)Nc1ccc2c(c1)NC(=O)CO2

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.68
▸ MALT1 Q9UDY8 2/20 0.56
▸ ALDH1A1 P00352 3/20 0.53
▸ MAPT P10636 3/20 0.53
▸ PRKCI P41743 2/20 0.51
▸ VCP P55072 3/20 0.50
▸ POLB P06746 1/20 0.50
▸ TRPV1 Q8NER1 4/20 0.48
▸ GRM5 P41594 1/20 0.47
▸ CYP2C9 P11712 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ CYP3A4 P08684 1/20 0.46
▸ CYP19A1 P11511 1/20 0.46
▸ GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14073674 0.92 KMT2A (0.56) KMT2AMALT1ALDH1A1MAPTPRKCI
SCHEMBL14073592 0.88 KMT2A (0.69) KMT2AMALT1ALDH1A1MAPTPOLB
SCHEMBL14073610 0.86 KMT2A (0.67) KMT2AMALT1ALDH1A1MAPTPOLB
SCHEMBL14073490 0.85 KMT2A (0.59) KMT2AMALT1ALDH1A1MAPTPOLB
SCHEMBL14073561 0.85 KMT2A (0.58) KMT2AMALT1ALDH1A1MAPTPRKCI
SCHEMBL14073107 0.82 TSHR (0.56) KMT2AALDH1A1POLB
SCHEMBL14073568 0.82 KMT2A (0.67) KMT2AMALT1ALDH1A1MAPTPOLB
SCHEMBL14073504 0.82 KMT2A (0.63) KMT2AMALT1ALDH1A1MAPTPOLB
SCHEMBL14073478 0.81 KMT2A (0.62) KMT2AMALT1ALDH1A1MAPTPOLB
SCHEMBL14073480 0.81 KMT2A (0.62) KMT2AMALT1ALDH1A1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-09-11 — — US disclosed
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety MMP12, MMP13, MMP25 KMT2A 2900/4885MALT1 4139/4885ALDH1A1 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback